HRC
VIR icon

Hoertkorn Richard Charles’s Vir Biotechnology VIR Stock Holding History

Hoertkorn Richard Charles’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-4,050
Closed -$109K – 83
2020
Q4 		$109K Hold
4,050
– – 0.06% 51
2020
Q3 		$139K Hold
4,050
– – 0.09% 47
2020
Q2 		$166K Buy
+4,050
New +$136K 0.11% 44

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.57B AUM 15.23% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Hoertkorn Richard Charles's VIR Position: Q1 2021 in Review

Hoertkorn Richard Charles sold out of Vir Biotechnology (VIR) in Q1 2021, closing a stake of 4,050 shares — an estimated $109K sold.

Hoertkorn Richard Charles first reported a position in VIR in Q2 2020 and held it in 3 quarters. The position peaked at $166K in Q2 2020. 157 funds tracked by Wall St. Rank hold VIR as of Q1 2021.

  • Hoertkorn Richard Charles reported no remaining Vir Biotechnology position as of Q1 2021 after selling out during the quarter.
  • Hoertkorn Richard Charles sold 4,050 Vir Biotechnology shares in Q1 2021, an estimated $109K.
  • Hoertkorn Richard Charles first reported a position in Vir Biotechnology in Q2 2020 and held it in 3 quarters.
  • Hoertkorn Richard Charles's Vir Biotechnology position peaked at $166K in Q2 2020.
  • 157 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2021.

Based on Hoertkorn Richard Charles's 13F filing for Q1 2021, filed 21 Apr 2021.